Hit enter to search or ESC to close

News

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy

Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy ...

Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in investor meetings at the Benchmark Company Healthcare House Call Conference.The conference is taking place virtually on Thursday, 2 June 2022. About ...

Appendix 4C – Q3 FY22 Quarterly Cash Flow Report

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st March 2022 (Q3 FY22). The Company’s cash position on 31 March 2022 was $32.6M ...

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that the United Kingdom Medicines & Healthcare products Regulatory Agency (MHRA) has accepted Alterity’s clinical trial authorization (CTA) request to conduct its Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. “Approval by the ...

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

The data provides further validation of the intended Phase 2 study design Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced that new data are being presented in a poster session today from the Company’s ongoing Biomarkers of progression in Multiple System Atrophy (bioMUSE) study today at the American Academy of Neurology (AAN) Annual Meeting taking ...

Alterity Therapeutics to Participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum. At the conference, Dr Stamler will be featured on a panel entitled, “Progress ...

WEBCAST LINK: 34th Annual Roth Conference

All stakeholders of Alterity Therapeutics, are invited to register to view the Company’s presentation at the 34th Annual Roth Conference. The conference is taking place Monday, 14 March and Tuesday, 15 March 2022 in Dana Point, California, USA. Link to registration: https://wsw.com/webcast/roth43/athe/1810184

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Study demonstrates reduction of α-synuclein aggregation and preservation of neurons Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson’s Disease. MSA is ...

Appendix 4C – Q2 FY22 Quarterly Cash Flow Report

Highlights: NZ’s regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter patent secures exclusivity for a new class of compounds targeting Parkinson’s and Alzheimer’s diseases Active investor relations program in ...

Receive news from Alterity Therapeutics